Docosanol
Abreva, Docosanol (docosanol) is a small molecule pharmaceutical. Docosanol was first approved as Abreva on 2000-07-25. It is used to treat blister in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Abreva, Docosanol
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abreva | ANDA | 2024-06-20 |
| amazon basics docosanol | ANDA | 2026-03-18 |
| cold sore fever blister | ANDA | 2025-12-29 |
| cold sore fever blister treatment | ANDA | 2026-08-06 |
| cold sore treatment | ANDA | 2025-12-29 |
| cold sore treatment docosanol | ANDA | 2025-04-11 |
| docosanol | ANDA | 2026-09-23 |
| julie cold sore treatment | ANDA | 2024-07-19 |
| klm | ANDA | 2024-09-25 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Herpes simplex | D006561 | — | B00 | — | 1 | — | 1 | — | 2 |
| Herpes labialis | D006560 | EFO_1001347 | B00.1 | — | 1 | — | 1 | — | 2 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Herpetic stomatitis | D013283 | EFO_0007307 | — | — | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin abnormalities | D012868 | — | Q82.9 | — | — | — | — | 1 | 1 |
| Skin aging | D015595 | EFO_0005422 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Docosanol |
| INN | — |
| Description | Docosan-1-ol is a long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It has a role as an antiviral agent. It is a long-chain primary fatty alcohol and a fatty alcohol 22:0. It derives from a hydride of a docosane. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCCCCCCCCCCCCCO |
Identifiers
| PDB | — |
| CAS-ID | 661-19-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200453 |
| ChEBI ID | 31000 |
| PubChem CID | 12620 |
| DrugBank | DB00632 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Docosanol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 732 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,165 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use